SCHEMBL19965851

SCHEMBL19965851

CNc1ccc2ccc(C)nc2c1N

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.52
RAB9A P51151 1/20 0.52
CCR5 P51681 1/20 0.52
GLO1 Q04760 2/20 0.40
METAP2 P50579 1/20 0.40
SLC40A1 Q9NP59 3/20 0.39
NFKBIA P25963 3/20 0.39
RELA Q04206 3/20 0.39
PARP1 P09874 1/20 0.39
AGTR1 P30556 1/20 0.36
PAX8 Q06710 1/20 0.36
LMNA P02545 2/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
CASP6 P55212 1/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
GAA P10253 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6776759 0.77 NOS3 (0.39) CCR1RAB9ACCR5LMNAKDM4E
SCHEMBL10309544 0.76 LMNA (0.59) CCR1RAB9ACCR5GLO1METAP2
SCHEMBL23192966 0.75 CCR1 (0.61) CCR1RAB9ACCR5GLO1METAP2
SCHEMBL7453433 0.75 CCR1 (0.61) CCR1RAB9ACCR5GLO1METAP2
SCHEMBL21101408 0.75 MAPT (0.36) MAPT
SCHEMBL26307346 0.74 GLO1 (0.62) CCR1RAB9ACCR5GLO1METAP2
SCHEMBL20838492 0.74 CCR1 (0.58) CCR1RAB9ACCR5GLO1METAP2
SCHEMBL9374249 0.73 CCR1 (0.60) CCR1CCR5SLC40A1NFKBIAPARP1
Neocuproine SCHEMBL4394429 0.71 CCR1 (0.88) CCR1RAB9ACCR5GLO1METAP2
Neocuproine SCHEMBL2415313 0.71 CCR1 (0.88) CCR1RAB9ACCR5GLO1METAP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10570156-B2 Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors SUNOVION PHARMACEUTICALS INC. (US) 2020-02-25 US disclosed
US-20180072759-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF SUNOVION PHARMACEUTICALS INC. 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072759-A1 HETEROARYL COMPOUNDS AND METHODS OF USE THEREOF COMT, GPR119, NLN CCR1 3722/4885RAB9A 957/4885CCR5 4191/4885
US-10570156-B2 Substituted imidazo[1,2-a]pyridines as PDE-10 inhibitors PDE3A, PDE2A, PDE5A CCR1 2639/4885RAB9A 595/4885CCR5 2720/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.